| Literature DB >> 23110085 |
Shifeng Huang1, Wei Dai, Shan Sun, Xiaojiao Zhang, Liping Zhang.
Abstract
BACKGROUND: Simultaneous resistance to aminoglycosides and fluoroquinolones in carbapeneme non-susceptible (CNS) isolates will inevitably create problems. The present study was performed to characterize the prevalence of the plasmid-mediated quinolone resistance determinants (QRDs) and aminoglycoside resistance determinants (ARDs) among the CNS Enterobacter cloacae (E. cloacae) isolates in a Chinese teaching hospital, and to acquire their molecular epidemiological characteristics.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23110085 PMCID: PMC3479141 DOI: 10.1371/journal.pone.0047636
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
PCR primers for β-lactams, quinolinones and aminoglycosides resistance genes.
| Genes | Primers | Sequences (5′-3′)’) | Amplicon length(bp) |
|
| F |
| 892 |
| R |
| ||
|
| F |
| 820 |
| R |
| ||
|
| F |
| 920 |
| R |
| ||
|
| F |
| 488 |
| R |
| ||
|
| 1-F |
| 292 |
| 1-R |
| ||
| 2-F |
| 287 | |
| 2-R |
| ||
|
| F |
| 919 |
| R |
| ||
|
| F |
| 1031 |
| R |
| ||
|
| F |
| 479 |
| R |
| ||
|
| F |
| 355 |
| R |
| ||
|
| F |
| 413 |
| R |
| ||
|
| F |
| 469 |
| R |
| ||
|
| F |
| 428 |
| R |
| ||
|
| F |
| 544 |
| R |
| ||
|
| F |
| 395 |
| R |
| ||
|
| F |
| 846 |
| R |
| ||
|
| F |
| 769 |
| R |
| ||
|
| F |
| 480 |
| R |
|
Relevant phenotypic and genotypic characteristics of the 35 carbapeneme non-susceptible (CNS) Enterobacter cloacae (E. cloacae) strains.
| No. | MIC(mg/ml) | Drug resistance profiles | detection of resistance genes | PFGE pattern | ||||
| IMP | ETP | Carbape-nemase | ESBL | QRD | ARD | |||
| 1 | 2 | 16 | CRO, CAZ, FEP, CIP, LEV, AK |
| - | - |
| A1 |
| 2 | 2 | 16 | CRO, CAZ, FEP, CIP,LEV, GM, TOB, AK |
|
|
|
| A2 |
| 3 | 2 | 16 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| A1 |
| 4 | 0.25 | 4 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK | - |
|
|
| E1 |
| 5 | 2 | 16 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| A2 |
| 6 | 0.25 | 4 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| K |
| 7 | 8 | 8 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| F |
| 8 | 8 | 2 | CRO, CAZ, FEP, GM, TOB, AK |
|
|
|
| G |
| 9 | 1 | 16 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| B1 |
| 10 | 1 | 16 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| B1 |
| 11 | 0.25 | 4 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| C2 |
| 12 | 0.25 | 4 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| C1 |
| 13 | 0.25 | 4 | CRO, CAZ, FEP |
|
|
|
| J |
| 14 | 0.25 | 2 | CRO, CAZ, FEP, CIP, LEV, GM, TOB |
|
|
|
| I |
| 15 | 8 | 8 | CRO, CAZ, FEP |
|
|
|
| H |
| 16 | 0.25 | 4 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| D2 |
| 17 | 0.25 | 4 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| D1 |
| 18 | 1 | 16 | CRO, CAZ, CIP, LEV, GM, TOB |
|
|
|
| B2 |
| 19 | 0.25 | 2 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| E2 |
| 20 | 2 | 16 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| E3 |
| 21 | 0.25 | 2 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| E1 |
| 22 | 2 | 16 | CRO, CAZ, FEP, CIP, LEV, GM, TOB, AK |
|
|
|
| E3 |
| 23 | 16 | 16 | CRO, FEP, CAZ, CIP, LEV, GM, TOB |
|
|
|
| L1 |
| 24 | 64 | 32 | CRO, FEP, CAZ, CIP, LEV, GM, TOB |
|
|
|
| L2 |
| 25 | 32 | 32 | CRO, FEP, CAZ, CIP, LEV, GM, TOB, AK |
|
|
|
| L1 |
| 26 | 2 | 16 | CRO, FEP, CAZ, CIP, LEV, GM, TOB, AK |
|
|
|
| O |
| 27 | 32 | 16 | CRO, FEP, CAZ, CIP, LEV, GM, TOB |
|
|
|
| N |
| 28 | 0.5 | 8 | CRO, FEP, CAZ, CIP, LEV, GM, TOB, AK |
|
|
|
| P |
| 29 | 0.125 | 4 | CRO, FEP, CAZ, CIP, LEV, GM, TOB, AK |
|
|
|
| ND |
| 30 | 0.25 | 4 | CRO, FEP, CAZ, CIP, LEV, GM, TOB, AK |
|
|
|
| ND |
| 31 | 0.25 | 4 | CRO, FEP, CAZ, CIP, LEV, GM, TOB |
|
|
|
| M |
| 32 | 0.125 | 4 | CRO, FEP, CAZ, CIP, LEV |
|
|
|
| Q |
| 33 | 4 | 8 | CRO, CAZ, CIP, LEV, GM, TOB, AK |
|
|
|
| E3 |
| 34 | 0.125 | 1 | CRO, FEP, CAZ, CIP,LEV, GM, TOB, AK |
|
|
|
| E2 |
| 35 | 64 | 32 | CRO, FEP, CAZ, CIP, LEV, GM,TOB |
|
|
|
| O |
ND: not determined.
MICs of antibiotics for the clinical No. 35 E. Cloacae strain (donor strain), E. coli EC600, representative transconjugant, E. Coli DH5? and representative transformant.
| antibiotics | MIC (µg/ml) | ||||
| EC No.35 | EC600 | Transconjugant | DH5? | Transformant | |
| AMP | ≥32 | 16 | ≥32 | ≤2 | ≥32 |
| AMS | ≥32/16 | 4/2 | ≥32/16 | ≤2/1 | ≥32/16 |
| PTZ | ≥128/4 | ≤4/0.125 | ≥128/4 | ≤4/0.125 | 64/2 |
| CFZ | ≥64 | ≤4 | ≥64 | ≤4 | ≥64 |
| CTT | ≥64 | ≤4 | ≥64 | ≤4 | 32 |
| CRO | ≥64 | ≤1 | ≥64 | ≤1 | ≥64 |
| CAZ | ≥64 | ≤1 | ≥64 | ≤1 | ≥64 |
| FEP | ≥64 | ≤1 | 16 | ≤1 | 8 |
| AZT | ≥64 | ≤1 | ≤1 | ≤1 | ≤1 |
| IMP | ≥16 | ≤1 | ≥16 | ≤1 | ≥16 |
| ETP | ≥8 | ≤0.5 | ≥8 | ≤0.5 | ≥8 |
| CIP | ≥4 | ≤0.25 | ≥4 | ≤0.25 | 0.5 |
| LEV | ≥8 | 0.5 | 4 | ≤0.25 | 1 |
| GM | ≥16 | ≤1 | ≤1 | ≤1 | ≤1 |
| TOB | 8 | ≤1 | ≤1 | ≤1 | ≤1 |
| AK | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 |
Eight representative transconjugants and transformants were respectively collected for antibiotic susceptibility test by the AST GN-13 card, and the representative results were shown.
Abbreviations used: ampicillin (AMP), ampicillin/sulbactam (AMS), piperacillin/tazobactam (PTZ), cefazolin (CFZ), cefotetan (CTT), ceftazidime (CAZ), ceftriaxone (CRO), cefepime (FEP), aztreonam (AZT), ertapenem (ETP), imipenem (IMP), ciprofloxacin (CIP), levofloxacin (LEV), amikacin (AK), gentamicin (GM), tobramycin (TOB).
Drug resistance genes detected from the clinical No. 35 E. Cloacae strain (donor strain), E. coli EC600, transconjugants, E. Coli DH5? and transformants using their plasmids as PCR templates.
| Genes | Stains | ||||
| EC No.35 | EC600 | transconjugant | DH5? | transformant | |
|
| • | • | • | ||
|
| • | • | • | ||
|
| • | • | |||
|
| • | • | • | ||
|
| • | • | |||
|
| • | ||||
•denotes positive.
Figure 1PFGE patterns of 35 CNS E. cloacae isolates.
PFGE fingerprinting was performed according to the “methods” section. Chromosomal DNA restriction patterns were interpreted by the Tenover's criteria. M: Lambda DNA Ladder; A1-Q: representative isolates with different genotype from A to Q.